Portable Oxygen Concentrators Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

Portable Oxygen Concentrators (POCs) are compact, battery-operated medical devices that concentrate oxygen from ambient air, making them suitable for patients requiring long-term oxygen therapy who wish to maintain mobility. The broader oxygen concentrators market, encompassing both portable and stationary units, is projected to reach roughly $1.71 billion by 2030 at a 6.1 percent CAGR, while the portable-only segment is valued at approximately $1.38 billion in 2026 and shows comparable growth momentum. The market has benefited from a structural shift away from high-pressure oxygen cylinders toward concentrator-based solutions across home care, institutional, and travel-use settings.

• •Portable oxygen concentrator segment valued at approximately $1.38 billion in 2026, up from the prior year, reflecting sustained demand growth.
• •Broader oxygen concentrator market projected to reach roughly $1.71 billion by 2030 from approximately $1.21-1.27 billion in 2025 at a CAGR near 6 percent.
• •Long-term oxygen therapy adoption in home-care settings is a primary market catalyst, supported by declining device costs and improved portability.

The global burden of chronic respiratory diseases, particularly chronic obstructive pulmonary disease, asthma, and interstitial lung disease, continues to rise, amplified by aging populations, air pollution, and persistent smoking rates in certain regions. Home-based oxygen therapy is increasingly preferred over institutional care due to lower costs, improved patient quality of life, and evolving clinical guidelines that endorse ambulatory oxygen use for broader patient profiles. Reimbursement frameworks in major healthcare systems, particularly in North America and parts of Europe, increasingly cover POC devices, directly expanding the addressable patient population.

• •Rising prevalence of COPD and other chronic respiratory conditions globally drives sustained demand for long-term oxygen therapy solutions.
• •A shift toward home-based and ambulatory care models reduces reliance on hospital infrastructure and elevates portable oxygen concentrator adoption.
• •Expanding reimbursement coverage by public and private payers lowers cost barriers and broadens the eligible patient base in key markets.

Portable oxygen concentrators are broadly classified into continuous-flow and pulse-dose delivery types, with pulse-dose devices dominating the portable segment due to their smaller form factor, lighter weight, and superior battery endurance suited for active users. Geographically, North America holds the largest market share, supported by high COPD prevalence, favorable reimbursement policies, and a well-developed home healthcare infrastructure. The Asia-Pacific region is projected to register the fastest growth rate, driven by improving healthcare access, rising respiratory disease burden, and increasing medical device adoption in emerging economies.

• •Pulse-dose portable concentrators represent the dominant product type in the portable segment due to extended battery life and lighter weight compared to continuous-flow units.
• •North America commands the largest regional market share, anchored by high respiratory disease prevalence and supportive reimbursement frameworks.
• •Asia-Pacific is the fastest-expanding region, driven by rising healthcare spending, increasing awareness of respiratory therapies, and growing chronic disease burdens.

Who are the notable companies in the industry?

The portable oxygen concentrator market features a blend of established manufacturers and emerging specialists operating primarily across North America. **Inogen**, headquartered in Goleta, United States since 2001, is recognized as a leading specialist in portable oxygen concentrators, producing lightweight and travel-approved systems that deliver self-replenishing oxygen and support long-term therapy without the constraints of traditional tanks. **Oxygenium Ltd.**, founded in New York in 2018, is an innovative manufacturer developing a compact, ultra-portable oxygen generator with adjustable high-flow rates and 99% medical-grade oxygen output, targeted at emergency response, hospital, and home healthcare settings, with U.S. availability planned for 2025. **Home Oxygen Company**, based in Modesto since 2007, functions as a provider of oxygen therapy technologies and home medical equipment, offering portable units including the Respironics SimplyGo Mini and SimplyGo.

• •The market shows moderate consolidation, combining established diversified medical device manufacturers with specialized respiratory equipment producers.
• •Pressure swing adsorption using zeolite molecular sieves is the dominant production technology, with differentiation focused on miniaturization, flow precision, and battery efficiency.
• •Production and assembly capacity is concentrated in North America, Western Europe, and East Asia, aligned with major regulatory and healthcare demand centers.

What are the recent trends and outlook?

Miniaturization and improved battery chemistry are enabling lighter, longer-lasting devices that expand use cases to travel, outdoor activity, and physically active patient populations. Digital connectivity features, including Bluetooth-enabled monitoring, mobile app integration, and remote patient data transmission, are becoming increasingly common, supporting the broader telehealth and remote patient monitoring movement. Over the 2026-2030 horizon, the market is expected to sustain its approximate 6 percent annual growth trajectory as technology improvements drive price reductions, reimbursement coverage broadens, and clinical evidence supporting ambulatory oxygen therapy expands.

• •Battery technology improvements and miniaturization are extending the operational viability of portable concentrators for more active patient profiles.
• •Integrated digital monitoring and telehealth connectivity are emerging as product differentiators, aligning with remote patient care adoption.
• •The market is forecast to sustain a CAGR near 6 percent through 2030, supported by technology maturation, price declines, and expanding clinical indications.